<DOC>
	<DOCNO>NCT02850107</DOCNO>
	<brief_summary>This study design collect information procedure routine care treat blockage blood vessel upper part participant 's leg . This study data collection reason help doctor gain good understand treatment disease blood vessel legs . You treat two device routine , standard care , doctor treat blockage blood vessel leg . The treatment blockage narrow cause plaque build-up blood vessel . Data collect assess length time blood vessel prevent re-narrowing twenty-four ( 24 ) month procedure .</brief_summary>
	<brief_title>DiRectional AthErectomy + Drug CoAted BaLloon Treat Long , CalcifIed FemoropopliTeal ArterY Lesions</brief_title>
	<detailed_description>This prospective study evaluate safety effectiveness two FDA 510 ( k ) clear DA product ( Medtronic HawkOne® TurboHawkM ) 19-21 FDA approve drug-coated balloon ( Medtronic IN.PACT® Admiral® ) 22 use combination debulk moderate severely calcified femoropopliteal artery atherosclerotic lesion define publish Peripheral Arterial Calcium Scoring System ( PACSS ) follow treatment Medtronic IN.PACT® Admiral® DCB prevention restenosis assess 12-month follow-up . The data independently adjudicate angiographic DUS core lab . An independent IVUS core lab determine change maximal luminal plaque area , pre- post-atherectomy post-adjunctive DCB therapy adjudicate assessment debulking effectiveness . The operator blind IVUS image procedural success base usual customary angiographic visual assessment . The post-atherectomy plaque debulking effectiveness ( change plaque area ) vascular calcium severity assess IVUS correlate angiographic metric RVD , pre- post-treatment MLD , calcium grade ( use PACSS ) , lesion length , sub-intimal wire passage , CTO length , angiographic pattern restenosis patient sustain CD-TLR 12-months . All atherectomy specimen collect provided independent histology laboratory analysis calcium content vessel wall element . The amount embolic debris capture Spider® Distal Protection Device visually assess . The study validate PACSS definition moderate severe calcium location ( intimal , medial mixed ) relate intra-procedural Major Adverse Events ( MAEs ) 30-day clinical follow-up ( e.g. , grade D-F dissection require provisional stenting , vessel perforation require additional intervention surgery , vessel thrombosis require adjunctive technology and/or lytic agent , unplanned amputation , intra-procedure distal embolization , CD-TLR ) .</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>General 1 . Willing able provide inform consent ; 2 . Age ≥ 18 year age ; 3 . Clinical evaluation determines Rutherford Category 24 ; 4 . Willing comply study requirement ; 5 . All lab work within acceptable limit undergo percutaneous interventional procedure . 6 . Life expectancy , investigator 's opinion , least 24 month . Angiographic 1 . RVD ≥ 4mm ≤ 7mm ; 2 . Evidence ≥70 % de novo restenotic lesion occlusion target lesion define superficial femoral artery and/or popliteal artery , locate arterial segment start least 1 cm beyond Common Femoral Artery ( CFA ) bifurcation superficial profunda femoris artery ( proximal anatomical landmark ) distal P2 segment popliteal artery ; 3 . Total lesion/occlusion length : . ≥ 8 cm ≤ 18 cm 4 . Total occlusion length . ≥ 6 cm ≤10 cm 5 . Stenosis occlusion begin 1cm profundaSFA bifurcation ; 6 . Femoral popliteal stenosis occlusion extend beyond P2 popliteal segment ; 7 . Minimum 1 patent infrapopliteal vessel foot ≤ 50 % diameter stenosis ; 8 . Grade 3 4 intimal , medial and/or mixed calcification per PACSS judge operator time procedure ; 9 . Index lesion fit within guideline : 9.1 If two lesion ≤ 3 cm apart , treatment would allow single lesion provide contain segment moderate severe calcification total lesion length ≥ 8 cm ≤18 cm . 9.2 If one lesion within target vessel , separate &gt; 3 cm normal vessel , one lesion must designate investigator target lesion long lesion meet angiographic eligibility criterion . Only one index lesion permit analysis , study allow second lesion treat nontarget lesion . 10 . Infrapopliteal lesion , diagnose , stag treat &gt; 30 day index procedure . General 1 . Renal failure chronic kidney disease GFR ≤30 ml/min MDRD GFR ≤30 ml/min per 1.73m2 ( serum creatinine ≥2.5 mg/dL within 30 day index procedure ) ; 2 . Physician believe subject appropriate candidate study ; 3 . Previous infrainguinal intervention index limb within 30 day plan femoropopliteal intervention Angiographic 1 . Inability cross lesion/occlusion guidewire reentry device ; 2 . Inability guidewire reenter and/or remain true lumen prior enrollment ; 3 . Instent restenosis target lesion , recognition stent ( patent restenotic within femoropopliteal segment index limb ; 4 . Aneurysm locate target vessel aneurysmal vessel ; 5 . Acute thrombus index limb prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Atherectomy , Drug-Coated Balloon</keyword>
</DOC>